Comparative Performance of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Gout in Type 2 Diabetes
Researchers compared the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on gout risk in patients with type 2 diabetes.
Researchers compared the beneficial effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on gout risk in patients with type 2 diabetes.
The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.
Researchers sought to understand the unmet needs for patients and provide insight into achieving better treatment for gout.
Researchers determined the effect of serum urate-associated genetic variants on gout risk in individuals receiving diuretics vs those who were not.
Researchers assessed changes in the estimated glomerular filtration rate among patients with gout with moderate renal impairment, using a treat-to-target approach for gout.
Researchers assessed the criteria for gout remission and defined the criteria for a complete response in patients with chronic refractory gout.
Researchers compared the effectiveness and safety of naproxen with low-dose colchicine in the treatment of gout flares in primary care.
Researchers assessed the risk for gout among adults receiving a sodium-glucose cotransporter 2 inhibitor vs a glucagon-like peptide-1 receptor agonist.
This study reports the long-term renal outcomes of kidney biopsies performed at prespecified intervals to determine the safety and accuracy of tapering of maintenance immunosuppression.
Researchers investigated the clinical features and risk factors for gout during tuberculosis treatment in a South Korean population.